In The Press

In The Press2026-08-12T13:05:25-08:00
1403, 2024

Phyton shares new article published by iScience that demonstrates that QS-21 produced via plant cell culture for saponin-derived vaccine adjuvants can be commercially produced in a sustainable way

March 14th, 2024|

Phyton Biotech is pleased to announce a recent publication by iScience showcasing the successful application of its plant cell fermentation platform to derive an important compound.

2505, 2021

Phyton Biotech has received Regulatory Approval from China’s NMPA for its plant cell fermentation-derived Paclitaxel Active Pharmaceutical Ingredient.

May 25th, 2021|

Phyton Biotech is pleased to announce approval from China’s regulatory body – National Medical Products Administration (NMPA) - for Phyton’s Drug Master File for paclitaxel active pharmaceutical ingredient produced via plant cell fermentation (PCF®).

1101, 2021

Phyton Biotech Announces the Successful Establishment of Plant Cell Lines to Source Key Building Block for Treatment of Rare Dermatologic Conditions

January 11th, 2021|

Phyton Biotech’s Plant Cell Fermentation (PCF) technology has been successfully used to develop high-yielding plant cell lines of the source of cyclopamine, a key raw material for PellePharm’s patedigib topical gel.

Go to Top